Successful treatment of low‐risk myelodysplastic syndrome‐related anemia in patients with chronic kidney disease with daprodustat: A report of two cases
Hiroyoshi Kunimoto, Takayuki Sakuma, Takuma Ohashi, Mayoko Shirafuta, Hiroshi Teranaka, Hideaki Nakajima · 2024
Read Successful treatment of low‐risk myelodysplastic syndrome‐related anemia in patients with chronic kidney disease with daprodustat: A report of two cases by Hiroyoshi Kunimoto, Takayuki Sakuma, Takuma Ohashi, Mayoko Shirafuta, Hiroshi Teranaka, Hideaki Nakajima (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11647689.txt.
Description
Hiroyoshi Kunimoto and co-authors report two cases where a kidney drug also eased a blood disorder. Their 2024 report deals with low-risk myelodysplastic syndrome, a bone marrow fault that causes anemia. Both patients also had chronic kidney disease, which adds its own anemia.
The drug, daprodustat, is a pill first used for kidney anemia. It works by restoring a signal that tells the body to make more red blood cells. Options for the marrow disorder are few, and a pill that works evenly is wanted. In both cases the anemia improved on the drug. The authors present the pair as a hint worth testing in more patients, with care for safety as well.
Catalog record
| CREATOR | Hiroyoshi Kunimoto, Takayuki Sakuma, Takuma Ohashi, Mayoko Shirafuta, Hiroshi Teranaka, Hideaki Nakajima |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 12 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |